Clinical trials: EGFR-TKI Resistant Mutation
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations.
- Trial name
- SOLARA (NCT06706076)
- Testing
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 675 people
- Sponsor
- BlossomHill Therapeutics
NSCLC
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
This study will investigate the efficacy and safety of the combination of pembrolizumab and lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.
- Trial name
- NCT05078931
- Testing
- Pembrolizumab, Lenvatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Chest Hospital
EGFR Mutation Positive Non-small Cell Lung Cancer
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
- Trial name
- NCT01776684
- Testing
- EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Non Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)
In this clinical trial, investigators select FFPE and plasma samples of non-small cell lung cancer which are used for quantitative detection of four kinds of EGFR(Epidermal Growth Factor Receptor) mutations.
- Conditions
- Non Small Cell Lung Cancer, EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation
- Trial name
- NCT02661009
- Volunteers
- 1,000 people
- Sponsor
- GenoSaber
NSCLC, EGFR Activating Mutation
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET/CT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed…
- Conditions
- NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2
- Trial name
- NCT07685197
- Testing
- receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
Bronchial Neoplasms
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib…
- Trial name
- EATON (NCT03516214)
- Testing
- EGF816, Trametinib
- Where
- 7 sites in Germany, Spain
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Lung Cancer
Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
To evaluate the effect of re-administration of gefitinib to EGFR-mutated NSCLC patients who had been treated with at least one line of TKIs followed by another line of treatment (non-TKI)
- Trial name
- IRENE (NCT02025218)
- Testing
- Gefitinib standard dose
- Where
- 14 sites in Netherlands
- Volunteers
- 21 people
- Sponsor
- Amsterdam UMC, location VUmc
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
- Trial name
- NCT05256290
- Testing
- silevertinib (BDTX-1535) monotherapy
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Non-Small-Cell Lung Cancer
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
The purpose of the Phase 1b part of the study was to evaluate the safety and tolerability of ASP2215 in combination with erlotinib and determine the recommended phase 2 dose (RP2D) of ASP2215.
- Trial name
- NCT02495233
- Testing
- Gilteritinib, Erlotinib
- Where
- 4 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Global Development, Inc.
NSCLC Patients With EGFR Activating Mutation
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
The current first line treatment of patients with EGFR activating mutation lung cancer is EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of response rate and progression-free survival.
- Trial name
- FLARE (NCT02178397)
- Testing
- ERLOTINIB WITH CHEMOTHERAPY, CHEMOTHERAPY ONLY
- Where
- 35 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Francois Baclesse
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, EGFR Gene Mutation
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
- Trial name
- NCT06071013
- Testing
- Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- China Medical University Hospital
EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.
- Conditions
- EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases
- Trial name
- NCT02972333
- Testing
- AZD9291 80mg oral each day, Radiation therapy
- Volunteers
- 150 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non Small Cell Lung Cancer
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
A phase II, open-label, multicenter, two cohorts, prospective clinical study to investigate the efficacy and safety of tislelizumab (anti-pd1 antibody) combined with chemotherapy with or without bevacizumab in non-squamous…
- Trial name
- NCT04405674
- Testing
- Tislelizumab, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada.
- Trial name
- PANORAMA (NCT03053297)
- Testing
- Patient Reported Outcomes
- Where
- 110 sites in Canada, China and 4 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
T790M Mutation Positive 2nd Line STandard of cAre Registry
The aim of the study is to collect real world information on patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who progressed after first line treatment with an approved Tyrosine-Kinase Inhibitor…
- Trial name
- T-STAR (NCT02368990)
- Where
- 49 sites in United States, China and 7 more
- Sponsor
- AstraZeneca
Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers
Numerous evidences verified that erlotinib could dramatically improve the PFS and OS of non-small cell lung cancers who harbor EGFR sensitive mutations, however, primary or secondary resistance will be developed after TKI…
- Trial name
- NCT02098954
- Testing
- Gemcitabine platinum combined with erlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of EDB-102 Injection in patients with advanced non-small cell lung cancer (NSCLC) who have liver metastases.
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases, EGFR Gene Mutation
- Trial name
- NCT07461727
- Testing
- EDB-102
- Volunteers
- 15 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences